[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Pins Medical Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641284","adaptive-dbs-for-pd-100641284",false,"NCT07635823","Adaptive DBS for PD","Adaptive vs Conventional Deep Brain Stimulation for Parkinson's Disease: A Multi-center Randomized Controlled Trial","SMART-DBS","Inclusion Criteria:\n\n* idiopathic Parkinson's disease\n* Hoehn \\& Yahr (HY) stage 2.5-4 during medication \"OFF\"\n* Subjects must meet one of the following:\n\n  1. Never underwent DBS surgery and suitable for bilateral STN or GPi DBS surgery;\n  2. Previous bilateral STN\u002FGPi DBS recipients with only one IPG who:\n* Demonstrate responsiveness to conventional cDBS therapy per investigator evaluation,\n* Consent to device replacement with G1010R DBS system.\n* Willing and physically\u002Fmentally able to complete all study visits and procedures\n* Capable of comprehending and providing written informed consent\n\nExclusion Criteria:\n\n* Presence of contraindications to deep brain stimulation (DBS) surgery.\n* Beck Depression Inventory-II (BDI-II) score \\> 25\n* Mini-Mental State Examination (MMSE) score \\\u003C 24 (adjusted for educational level)\n* Significant comorbidities that may interfere with DBS therapy per investigator assessment.\n* Pre-existing active non-DBS medical implants or metallic cranial implants\n* Requirement for diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT) during the study period\n* History of ablative neurosurgery or stem cell therapy for Parkinson's disease\n* Inability to complete ≥3 consecutive days of comprehensive motor\u002Fsleep diaries\n* Inability to maintain prescribed medication regimens or comply with protocol requirements\n* Current pregnancy, lactation, or planned pregnancy during the study period\n* Other conditions deemed by investigators to compromise study suitability\n* Participation in other interventional clinical trials within 4 weeks prior to consent","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of an adaptive deep brain stimulation (aDBS) system for managing Parkinson's disease symptoms. Researchers will compare closed-loop stimulation (which automatically adjusts therapy using real-time brain signals and sleep monitoring) against traditional continuous stimulation (fixed settings) in a randomized, double-blind, crossover study. Participants will undergo surgical implantation of PINS Medical's G1010R neurostimulator, followed by alternating treatment phases where each patient experiences both aDBS and conventional open-loop stimulation modes. Outcomes will assess improvements in without troublesome dyskinesia daily time, motor symptoms (e.g., tremors, rigidity), quality of life, and sleep quality across both therapy periods.",[27],"Parkinson Disease(PD)",[29,30,31,32,33],"Parkinson Disease","Deep brain stimulation","Adaptive DBS","Close-loop DBS","Dyskinesia","RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":38},"2026-05-16",{"date":42,"type":21},"2027-09-30",{"name":44,"class":45},"Beijing Pins Medical Co., Ltd","INDUSTRY",9,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100571624","a-trial-of-rehabilitation-paired-with-vns-for-motor-function-in-patients-with-stroke-repair-study-100571624","NCT06722677","A Trial of Rehabilitation Paired with VNS for Motor Function in Patients with Stroke (Repair Study)","A Multi-Center, Triple-Blind, Randomized, Sham-Controlled Trial Assessing the Efficacy and Safety of Rehabilitation Paired with Vagus Nerve Stimulation for Upper Extremity Motor Function in Patients with Ischemic Stroke (Repair Study)","Inclusion Criteria:\n\n1. Age ≥22 years and \\\u003C80 years, all gender is acceptable.\n2. History of unilateral supratentorial ischemic stroke ≥ 9 months but \\\u003C 10 years.\n3. Upper Extremity motor section of the Fugl-Meyer Assessment score ≥20 and ≤50.\n4. Right- or left-sided weakness of upper extremity.\n5. Ability to communicate, understand, and give appropriate consent. Subjects can follow trial commands.\n6. Subjects have good compliance and can complete the visits after surgery.\n\nExclusion Criteria:\n\n1. History of hemorrhagic stroke.\n2. Presence of ongoing dysphagia or aspiration difficulties.\n3. Prior injury to vagus nerve, either bilateral or unilateral.\n4. Subject receiving medication that may significantly interfere with actions of VNS on neurotransmitter systems at study entry, clinic rehabilitation follow-up timepoint, or home rehabilitation follow-up timepoint, such as centrally acting cholinoceptor blockers, centrally acting adrenoceptor blockers, norepinephrine re-uptake inhibitors, etc.\n5. Botox injections within 4 weeks prior to enrollment through the unmasking follow-up timepoint (Visit 6).\n6. Severe spasticity of the upper extremity (Modified Ashworth ≥ 3).\n7. Significant sensory loss of the upper extremity (Upper Extremity sensory section of the Fugl-Meyer Assessment score \\\u003C 6).\n8. Severe depression (Beck Depression Scale \\> 29).\n9. Current requirement, or likely future requirement, of diathermy.\n10. Current use of any other stimulation device, such as a pacemaker or other neurostimulator.\n11. Pregnancy or plans to become pregnant or to breastfeed during the study period.\n12. Participated in any other clinical trials within the preceding 3 months.\n13. Not considered to be applicable by the investigator.","22 Years","80 Years",{"count":57,"type":21},99,[24],"The goal of this clinical trial is to investigate the efficacy and safety of vagus nerve stimulation (VNS) paired with rehabilitation for enhancing upper extremity motor function after ischemic stroke.\n\nResearchers will compare the outcomes of active VNS paired with rehabilitation against sham VNS (the actual intensity is 0 mA) also paired with rehabilitation, in order to assess improvements in arm motor function post-stroke.\n\nParticipants in this study will undergo a surgical procedure to implant the VNS system and will subsequently recieve a 6 weeks in-clinic therapy, followed by an additional 6 weeks home exercise. During the final 6 weeks, participants will either recieve in-clinic therapy or maintain their home exercise, depending on their assigned group.",[61,62],"Ischemic Stroke","Upper Extremity Paresis",[64,61,65,62,66,67,68,69],"Stroke","Paresis","Vagus Nerve Stimulation","Neuromodulation","Randomized Controlled Trial","Rehabilitation","2024-12-09",{"date":72,"type":38},"2024-12-10",{"date":74,"type":38},"2024-11-19",{"date":76,"type":21},"2025-11",{"name":44,"class":45},16,""]